Home | About JCVJS | Editorial board | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |   Login 
Journal of Craniovertebral Junction and Spine
Search Articles   
    
Advanced search   
 


 
   Table of Contents  
LETTER TO EDITOR
Year : 2011  |  Volume : 2  |  Issue : 2  |  Page : 102-103  

The concern on clinical use of recombinant human bone morphogenetic protein-2


Wiwanitkit House, Bangkhae, Bangkok, Thailand

Date of Web Publication24-Aug-2012

Correspondence Address:
Viroj Wiwanitkit
Wiwanitkit House, Bangkhae, Bangkok 10160
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-8237.100077

Rights and Permissions

How to cite this article:
Wiwanitkit V. The concern on clinical use of recombinant human bone morphogenetic protein-2. J Craniovert Jun Spine 2011;2:102-3

How to cite this URL:
Wiwanitkit V. The concern on clinical use of recombinant human bone morphogenetic protein-2. J Craniovert Jun Spine [serial online] 2011 [cited 2020 Nov 24];2:102-3. Available from: https://www.jcvjs.com/text.asp?2011/2/2/102/100077

Sir,

The recent publication on the recombinant human bone morphogenetic protein-2 (rhBMP-2) is very interesting. [1] Hamilton et al. concluded that "100% fusion rate was achieved with adjunct use of rhBMP-2, with a safe and effective average rhBMP-2 dose of 2.38 mg per level." [1] Indeed, the use of rhBMP-2 is a new approach and the important concern is on the supporting evidences on this technique. [2] In this work, the total number of subjects is small; however, it can be a good supporting evidence. Another important concern is on the adverse effect of using this technique. Addullah et al. noted for the necessity on good examination with regard to side effect profiles. [2] Taghavi et al. noted that the "utility is limited by cost, and potential dose-dependent risks, such as local inflammatory reactions and ectopic bone formation." [3] An important side effect that is observed in the animal model studies is "joint space obliteration caused by cartilage overgrowth." [4] This has to be systematically evaluated in the long-term follow-up.

 
   References Top

1.Hamilton DK, Smith JS, Reames DL, Williams BJ, Shaffrey CI. Use of recombinant human bone morphogenetic protein-2 as an adjunct for instrumented posterior arthrodesis in the occipital cervical region: An analysis of safety, efficacy, and dosing. J Craniovert Jun Spine 2010;1:107-12  Back to cited text no. 1
    
2.Abdullah KG, Steinmetz MP, Benzel EC, Mroz TE. The state of lumbar fusion extenders. Spine (Phila Pa 1976) 2011;36:E1328-34.  Back to cited text no. 2
    
3.Taghavi CE, Lee KB, He W, Keorochana G, Murray SS, Brochmann EJ, et al. Bone morphogenetic protein binding peptide mechanism and enhancement of osteogenic protein-1 induced bone healing. Spine (Phila Pa 1976) 2010;35:2049-56.  Back to cited text no. 3
    
4.Alanay A, Chen C, Lee S, Murray SS, Brochmann EJ, Miyazaki M, et al. The short-term therapeutic effect of recombinant human bone morphogenetic protein-2 on collagenase-induced lumbar facet joint osteoarthritis in rats. Spine (Phila Pa 1976) 2008;33:1709-13.  Back to cited text no. 4
    




 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1697    
    Printed93    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal